Theragenomic Medicine

Blog Archives

Clinical evidence and implementation challenges for pharmacogenomic testing

Posted on September 18, 2019 by by

thassodotcom Posted in Allelic Variant, Genetic Background, Genetic Predisposition, Genetic Susceptibility, Personalized Medicine, Personomics, Pharmacogenetics, Thasso Post, Theragenomic Medicine No Comments ↓

September 18, 2019 – This post is an edited version of parts of a paper that appeared in the Journal of Personalised Medicine (JPM) a week ago und which addresses one of the important topics in connection with the themes of personalised medicine,

…

Tags: All of Us Project, Canadian Association of Genetic Counsellors, Clinical Pharmacogenetics Implementation Consortium (CPIC), Direct To Consumer Genetic Testing (DTCGT), Dutch Pharmacogenetics Working Group (DPWG), Genetic Testing, Next Generation Sequencing (NGS), Pharmacogenomics, PharmGKB, PREDICT Program, Right Dose, Right Drug, Right Time Protocol (RIGHT Protocol), Thasso Post, Theragenomic Medicine, Ubiquitous Pharmacogenomics Project (UPGX), US National Society of Genetic Counselors

Staying wakeful for the day: A second short sleep gene identified

Posted on September 6, 2019 by by

thassodotcom Posted in Allelic Variant, Genetic Predisposition, New Research, Personomics, Thasso Post, Theragenomic Medicine No Comments ↓

September 06, 2019 – Wakefulness varies largely among human individuals. Barring individuals suffering from diseases such as narcolepsy that may heavily dictate an individual’s daily sleep and wakefulness pattern, there are individuals in the general population who needs a lot of sleep and there are those who seemingly never sleep and still feel fit and good at performing their daily tasks.

…

Tags: ADRB1 Gene, DEC2 Gene, Genetic Mutation, Nacrolepsie, Short Sleep, Short Sleep Gene, Thasso Post, Theragenomic Medicine, Transcriptional Repressor, Wakefulness, β1-Adrenergic Receptor

FDA safety communication concerning E-cigarettes

Posted on September 5, 2019 by by

thassodotcom Posted in Adverse Drug Reaction [ADR], New Safety Information, Regulatory Announcement, Thasso Post, Theragenomic Medicine No Comments ↓

September 05, 2019 – An E-cigarette is a handheld battery-powered vaporizer that simulates smoking by providing some of the behavioral aspects of smoking, including the hand-to-mouth action of smoking, but without burning tobacco. Using an E-cigarette is known as “vaping” and the user is referred to as a “vaper.”

…

Tags: Aerosol, Cannabinoid, Center for Disease Control and Prevention (CDC), E-Cigarette, E-Cigarette Legislation, E-Liquid, Tetrahydrocannabinol (THC), Thasso Post, Theragenomic Medicine, Tobacco Products Directive, Vaping, Vapor

Variables of prospective response rates of PD-1/PD-L1 based therapies across cancers

Posted on August 28, 2019 by by

thassodotcom Posted in Genetic Background, Genetic Predisposition, New Research, On The Horizon, Personalized Medicine, Thasso Post, Theragenomic Medicine No Comments ↓

…

Tags: Colitis, Fatal Toxic Event, Hepatitis, Immune-Related Adverse Events (irAEs), Ipilimumab [Yervoy], Myocarditis, Neurotoxic Effects, Overall Response Rate (ORR), Pembrolizumab [Keytruda], Pneumonitis, Programmed Cell Death 1 Protein (PD-1), Programmed Cell Death 1 Protein Ligand 1 (PD-L1), Thasso Post, Theragenomic Medicine, These, Tumor Agnostic Therapy

Therapies that promote progressive multifocal leukoencephalopathy (PML)

Posted on August 23, 2019 by by

thassodotcom Posted in Adverse Drug Reaction [ADR], Commentary, Thasso Post, Theragenomic Medicine No Comments ↓

August 23, 2019 – Progressive multifocal leukoencephalopathy (PML) is a rare and often fatal viral disease characterized by progressive damage or inflammation of the white matter of the brain at multiple locations (i.e., multifocal). It is caused by the JC virus,

…

Tags: Abatacept (Orencia), Adalimumab (Humira), Alemtuzumab (Campath), Alemtuzumab (Lemtrada), Basiliximab (Simulaect), Belatacept [Nulojix], Belimumab (Benlista), Bevacizumab [Avastin], Brentuximab vedotin (Adectris), Carfizumab (Kyprolis), Cetuximab (Erbitux), Dimethyl Fumarate [Tecfidera], Efalizumab (Raptiva), Etanercept [Enbrel], Fingolimod (Gylenia), Ibritumomab tiuxetan (Zevalin), Immunosuppression, Infliximab [Remicade], JC Virus (JCV), Multiple Sclerosis (MS), Muromonab‐CD3 (Orthoclone OKT3), Natalizumab [Tysabri], Obinutuzumab (Gazyva), Ofatumumab (Arzerra), Progressive Multifocal Leukoencephalopathy (PML), Rituximab [Rituxan], Thasso Post, Theragenomic Medicine

Onasemnogene abeparvovec-xioi (Zolgensma): Approval strategy with manipulated data?

Posted on August 13, 2019 by by

thassodotcom Posted in Allelic Variant, Gene Therapy, Genetic Background, In The Press, Personomics, Thasso Post, Theragenomic Medicine No Comments ↓

August 13, 2019 – Onasemnogene abeparvovec-xioi (Zolgensma) is an adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.

…

Tags: American Food & Drug Administration (FDA), Gene Replacement Therapy, Gene Therapy, Onasemnogene Abeparvovec-xioi (Zolgensma), SMN1 Gene, Spinal Muscular Atrophy (SMA), Survival Motor Neuron 1 Gene (SMN1), Thasso Post, Theragenomic Medicine

Cystic fibrosis: CFTR-gene editing may cure this genetic disease

Posted on August 13, 2019 by by

thassodotcom Posted in Congenital, Gene Editing, Gene Therapy, Genetic Background, New Research, Personomics, Thasso Post, Theragenomic Medicine No Comments ↓

August 13, 2019 – A very significant research article by the title “Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing” has just appeared in the open access Journal Nature Communications. This work provide hope to patients with cystic fibrosis (CF) that in the nearer future CF may be curable,

…

Tags: 3272–26A>G CTFR Gene Mutation, 3849+10kbC>T CFTR Gene Mutation, CFTR Gene, CFTRΔF508, CRISPR-Cas9, Cystic Fibrosis (CF), Gene Correction, Gene Editing, Gene Mutation, Gene Splicing, Gene Therapy Clinical Trials, Thasso Post, Theragenomic Medizine

Black people with natural blonde hair – Everything is possible in genetics

Posted on August 7, 2019 by by

thassodotcom Posted in Allelic Variant, Ethnicity, Genetic Predisposition, New Research, Personomics, Thasso Post, Theragenomic Medicine No Comments ↓

August 07, 2019 – Blonde hair is a rare human phenotype found almost exclusively in Europe and Oceania. Human pigmentation varies considerably within and among populations and is a function of both variation in exposure to ultraviolet radiation (UVR) and the type and quantity of melanin produced in melanocytes and keratinocytes.

…

Tags: African Ancestry, Allelic Variant, Autosomal Recessive, Blonde Hair, Genetic Predisposition, Genetic Variant, Genome Wide Association Study (GWA), Genotyp [Homozygot], Inheritance, Melanesian People, Melanin, Oceania, Solomon Islands, Thasso Post, Theragenomics Medicine, Tyrosinase-Related Protein 1, TYRP1 Gene, Years Before Present (YBP)

ZRANB3 in African Populations: New Type 2 Diabetes risk locus identified

Posted on August 3, 2019 by by

thassodotcom Posted in Ethnicity, Genetic Background, Genetic Predisposition, Genetic Susceptibility, Personalized Medicine, Personomics, Thasso Post, Theragenomic Medicine No Comments ↓

August 03, 2019 – Africa is considered the original cradle of all humanity, to which all humans can trace their genetic origin. This may be very interesting in the context of diseases that are due to genetic predispositions both in todays African populations and in all the populations descendant of African origin worldwide.

…

Tags: 1000 Genomes Project (1KGP), African Population, Genome Aggregation Database (GnomAD), Risk Locus, T2D, Thasso Post, Theragenomic Medicine, Type 2 Diabetes, ZRANB3 Gene

Risk loci for post-traumatic stress disorder (PTSD)

Posted on August 1, 2019 by by

thassodotcom Posted in Allelic Variant, Ethnicity, Genetic Background, Genetic Predisposition, New Research, Thasso Post, Theragenomic Medicine No Comments ↓

August 01, 2019 – Post-Traumatic Stress Disorder (PTSD) is a mental disorder that can develop after a person is exposed to a traumatic event, such as sexual assault, warfare, traffic collisions, or other threats on a person’s life. Symptoms may include disturbing thoughts,

…